Comparison of Progressive Antithrombin Activity and the Concentration of Three Thrombin Inhibitors in Nephrotic Syndrome

Summary

In order to compare the plasmatic progressive antithrombin activity to the concentration of three thrombin inhibitors, antithrombin III (AT III), α₂ macroglobulin (α₂, M), α₁ anti-trypsin (α₁ AT) in nephrotic syndrome, a prospective study was carried out on a group of 28 children affected with the disease. A dramatic reduction of the level of AT III and of α₁ AT, two inhibitors of molecular weight close to that of albumin, was observed. The decreased level of AT III was counterbalanced by an increase in α₂ M. This phenomenon accounts for the increased progressive antithrombin activity observed in all the affected children. It is suggested that the above compensatory mechanism explains the absence of thrombotic accidents in this series and that the benefit of heparin therapy is doubtful in these conditions.

Keywords

Antithombin III - α₂ macroglobulin - α₁ anti-trypsin - Thrombin inhibitors - Nephrotic syndrome

• References

• 1 Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thrombos Diathes Haemorrh 1970; 24: 562-571
• 2 Kendall AG, Lohmann RC, Dossetor JB. Nephrotic syndrome. A hypercoagulable state Arch Int Med 1971; 127: 1021-1027
• 3 Thomson C, Forbes CD, Prentice CR M, Kennedy AC. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Quat J Med 1974; 43: 399-407
• 4 Bernard D, Gouault-Heilmann M, Ansquer JC, Levent M, Ladieu D, Lagrue G. Etude des facteurs de l’hémostase au cours des syndromes néphrotiques. Interprétation pathogénique et déduction thérapeutiques Ann Med Interne 1977; 128: 325-333
• 5 Loirat C, Pillion G, Schlegel N, Douenias R, Mathieu H. Etude des protéines de la coagulation et de la fibrinolyse au cours des syndromes néphrotiques de l’enfant. Arch Fr Pédiat 1979; 36: 56-63
• 6 Kauffmann RH, Veltkamp JJ, Tilburg NH V, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-613
• 7 Guillot M, Fischer AM, Goldszmidt D, Bacri JL, Gagnadoux MF, Usberti M, Josso F, Broyer M. Syndrome néphrotique déficit en antithrombine DI et thromboses à répétition. Intérêt des antagonistes de la vitamine K Arch Fr Pédiat 1979; 36: 930-933
• 8 Jorgensen KA, Stoffersen E. Antithrombin ID and the nephrotic syndrome. Scand J Haematol 1979; 22: 442-448
• 9 Bouissou F, Barthe Ph, Boneu B. Déficits acquis en facteur XII et antithrombine in (AT ID) dans les néphroses de l’enfant. Résultats préliminaires Nouv Presse Med 1980; 9: 1778 (letter)
• 10 Howie PW, Prentice CR M, McNicol GP. A method of antithrombin estimation using plasma defibrinated with ancrod. Br J Haemat 1973; 25: 101-110
• 11 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Ann Biochem 1966; 15: 45-52
• 12 Harpel PC, Rosenberg RD. α2-Macroglobulin and antithrombinheparin cofactor: modulators of hemostatic and inflammatory reactions. In Hemostasis and Thrombosis. Ed Spaet TH. Publ: Grune et Stratton; (N.Y.): 1976. 3 145-189
• 13 Kluthe R, Hagemann U, Kleine N. The turnover of α2-macroglobulins in the nephrotic syndrome. Vox Sang 1967; 12: 308-311
• 14 Tunstall AM, Merriman JM L, Milne I, James K. Normal and pathological serum levels of α2-macroglobulins in men and mice. J Clin Path 1975; 28: 133-139
• 15 Fischer AM, Tapon-Bretaudiere J, Bros A, Josso F. Respective roles of antithrombin III and α2-macroglobulin in thrombin inactivation. Thromb Haemostas 1981; 45: 51-54
• 16 Abildgaard U, Fagerhol MK, Egeberg O. Comparison of progressive antithrombin activity and the concentrations of three thrombin inhibitors in human plasma. Scand J Clin Lab Invest 1970; 26: 349-354
• 17 Fischer AM, Bros A, Rafowicz S, Josso F. Inhibition par l’héparine de l’activité antithrombique de l’α2-macroglobulin. C R Acad Sc Paris 1979; 288: 887-889